A Novel Adeno-Associated Viral Variant for Efficient and Selective Intravitreal Transduction of Rat Müller Cells
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The pathologies of numerous retinal degenerative diseases can be attributed to a multitude of genetic factors, and individualized treatment options for afflicted patients are limited and cost-inefficient. In light of the shared neurodegenerative phenotype among these disorders, a safe and broad-based neuroprotective approach would be desirable to overcome these obstacles. As a result, gene delivery of secretable-neuroprotective factors to Müller cells, a type of retinal glia that contacts all classes of retinal neurons, represents an ideal approach to mediate protection of the entire retina through a simple and innocuous intraocular, or intravitreal, injection of an efficient vehicle such as an adeno-associated viral vector (AAV). Although several naturally occurring AAV variants have been isolated with a variety of tropisms, or cellular specificities, these vectors inefficiently infect Müller cells via intravitreal injection. METHODOLOGY/PRINCIPAL FINDINGS: We have previously applied directed evolution to create several novel AAV variants capable of efficient infection of both rat and human astrocytes through iterative selection of a panel of highly diverse AAV libraries. Here, in vivo and in vitro characterization of these isolated variants identifies a previously unreported AAV variant ShH10, closely related to AAV serotype 6 (AAV6), capable of efficient, selective Müller cell infection through intravitreal injection. Importantly, this new variant shows significantly improved transduction relative to AAV2 (>60%) and AAV6. CONCLUSIONS/SIGNIFICANCE: Our findings demonstrate that AAV is a highly versatile vector capable of powerful shifts in tropism from minor sequence changes. This isolated variant represents a new therapeutic vector to treat retinal degenerative diseases through secretion of neuroprotective factors from Müller cells as well as provides new opportunities to study their biological functions in the retina.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






![Figure 7 rAAV6 N451D expression following intravitreal injection. Confocal imaging of immunostained transverse retinal sections 3 weeks post-injection of rAAV6 N451D dsCAG-GFP (B, C). GFP expression analysis (B) and overlay with GS (C) reveal this mutant to be sufficient for an intravitreal Müller infection, though at a reduced efficiency relative to ShH10 (fig. 1D, F). Mapping of this mutation onto the AAV6 capsid subunit VP3 (A) (blue) shows its location near the three-fold axis of symmetry of the assembled capsid. Three-dimensional models of the AAV6 VP3 subunit were generated using Swiss Model with the coordinates of AAV2 (Protein Databank accession no. 1LP3) supplied as a template and images were rendered in Pymol and Rasmol. Additionally, the D532N mutation (green) maps near the HSPG-binding domain (purple) [35].](https://figures.cochat.ai/paper-figures/a1b918ae052e44d5bf5134ffbd3eb284/a-novel-adeno-associated-viral-variant-for-efficient-and-selective-intravitreal-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent work has developed AAV variants that are capable of infecting both Muller glia and photoreceptors across the retina following intravitreal administration, making intravitreal injections a promising alternative.24,25”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An example are the rAAV6 variants ShH10 and ShH10-Y445F that efficiently infect rat, mouse, and human Müller glial cells [60,62,272].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [272]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cahoy, J. D., Emery, B., Kaushal, A., Foo, L. C., Zamanian, J. L., Christopherson, K. S., Xing, Y., Lubischer, J. L., Krieg, P. A., Krupenko, S. A., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4178-07.2008 · Cited by 3,129 · cited 1×
“analogous roles in the CNS [26,27,36,37].”
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“The therapeutic potential of AAV-mediated gene delivery to the retina has best been illustrated by the positive results from three phase I clinical trials for Leber’s Congenital Amaurosis (LCA), a rare autosomal recessive blinding disease caused by loss of function mutations in the visual cycle enzyme retinol isomeras…”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“The therapeutic potential of AAV-mediated gene delivery to the retina has best been illustrated by the positive results from three phase I clinical trials for Leber’s Congenital Amaurosis (LCA), a rare autosomal recessive blinding disease caused by loss of function mutations in the visual cycle enzyme retinol isomeras…”
BackgroundMüller cells in the healthy and diseased retina
BRINGMANN, A., PANNICKE, T., GROSCHE, J., FRANCKE, M., WIEDEMANN, P., SKATCHKOV, S., OSBORNE, N., & REICHENBACH, A. (2006) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2006.05.003 · Cited by 1,711 · cited 1×
“Müller cells serve numerous, significant physiological functions in the retina including but not limited to: metabolic support of neurons, K and water homeostasis, free radical scavenging and oxidative protection, neurotrophic secretion, and neurotransmitter and retinoid uptake and recycling [26].”
BackgroundXiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Cideciyan, A. V., Aleman, T. S., Boye, S. L., Schwartz, S. B., Kaushal, S., Roman, A. J., Pang, J.-J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 673 · cited 1×
“Subretinal administration of many of these AAV variants has led to efficient gene expression in a number of retinal neurons and epithelia, including photoreceptors and RPE [14,15], and it is thus the injection route employed by current clinical therapies to achieve sufficient transduction for rescue [2].”
BackgroundThe atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612 · cited 4×
“To characterize the in vitro infectivity of these mutants, and in particular their glycan dependence in light of the substantial role proteoglycans and glycoproteins play in AAV transduction [4,5,13], we analyzed their relative transduction efficiencies on a panel of cell types: Pro5, a Pro5 mutant (Lec1) deficient in…”
BackgroundInfluentialLagali, P. S., Balya, D., Awatramani, G. B., Münch, T. A., Kim, D. S., Busskamp, V., Cepko, C. L., & Roska, B. (2008) · Nature Neuroscience · doi:10.1038/nn.2117 · Cited by 582 · cited 1×
“selections could provide a more powerful approach to directly target specific cell types in the retina. For example, the targeting of engineered light gated channels to specific subpopulations of retinal cells, such as ON bipolar cells or ON/OFF retinal ganglion cells”
BackgroundDirected evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538 · cited 3×
“The resulting viral fractions were desalted and concentrated with Amicon Ultra-15 Centrifugal Filter Units to a final volume of 200 ml. Vector was then titered for DNase-resistant vector genomes by real time PCR relative to a standard.”
MethodSelf-citationInfectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, J. S., Wilcher, R., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2777-2785.2000 · Cited by 532 · cited 1×
“. In addition, the capsid diversity found among natural AAV variants, or serotypes, isolated from human and nonhuman primate tissues accounts for its diverse tropisms, as AAV has been shown in animal models to deliver genes to cells in numerous tissues including the retina, brain, muscle, and lung”
Background
Cited by
Items 101–200 of 209
AAV-CRB2 protects against vision loss in an inducible CRB1 retinitis pigmentosa mouse model
Buck, T. M., Vos, R. M., Alves, C. H., & Wijnholds, J. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.12.012 · Cited by 25
“Since exposure of DL-AAA to the mouse retina, or loss of CRB1 or loss of CRB2 proteins in the mouse retina, causes disruptions at foci at the OLM, we examined whether mice with decreased levels of CRB proteins in MGCs are more sensitive to DL-AAA exposure than retinas with higher levels of CRB proteins in MGCs.”
BackgroundInfluentialNeuroinflammation as a cause of differential Müller cell regenerative responses to retinal injury
García-García, D., Vidal‐Gil, L., Parain, K., Lun, J., Audic, Y., Chesneau, A., Siron, L., Westendorp, D. V., Lourdel, S., Sánchez‐Sáez, X., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp7916 · Cited by 23
“This adenovirus (Shh10 variant) ( 59 ) allows the expression of a constitutively active form of YAP (YAP5SA), specifically in Müller cells ( 57 ).”
BackgroundSun, S., & Schaffer, D. V. (2018) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2017.12.011 · Cited by 24
Self-citationRetinal Remodeling: Concerns, Emerging Remedies and Future Prospects
Krishnamoorthy, V., Cherukuri, P., Poria, D., Goel, M., Dagar, S., & Dhingra, N. K. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00038 · Cited by 24
Strategies for Targeting Neural Circuits: How to Manipulate Neurons Using Virus Vehicles
Hui, Y., Zheng, X., Zhang, H., Li, F., Yu, G., Li, J., Zhang, J., Gong, X., & Guo, G. (2022) · Frontiers in Neural Circuits · doi:10.3389/fncir.2022.882366 · Cited by 27
“%) for Müller cells through intravitreal injection (Klimczak et al., 2009; Koerber et al., 2009).”
BackgroundBasche, M., Kampik, D., Kawasaki, S., Branch, M. J., Robinson, M. R., Larkin, F., Smith, A. J., & Ali, R. R. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.115 · Cited by 23
“46,47 This requires the AAV virion to penetrate the inner limiting membrane and * 200 l m of neural tissue, which several engineered serotypes have now been shown capable of doing.”
Barboni, M. T. S., Vaillend, C., Joachimsthaler, A., Liber, A. M. P., Khabou, H., Roux, M. J., Vacca, O., Vignaud, L., Dalkara, D., Guillonneau, X., et al. (2020) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.61.2.11 · Cited by 20
Self-citationVision-related convergent gene losses reveal SERPINE3’s unknown role in the eye
Indrischek, H., Hammer, J., Machate, A., Hecker, N., Kirilenko, B., Roscito, J., Hans, S., Norden, C., Brand, M., & Hiller, M. (2022) · eLife · doi:10.7554/elife.77999 · Cited by 21
Kotterman, M., Beliakoff, G., Croze, R., Vazin, T., Schmitt, C., Szymanski, P., Leong, M., Quezada, M., Holt, J., Barglow, K., et al. (2021) · doi:10.1101/2021.06.24.449775 · Cited by 20
Self-citationXie, L., Yin, Y., Jayakar, S. S., Kawaguchi, R., Wang, Q., Peterson, S. L., Shi, C., Turnes, B. L., Zhang, Z., Osés-Prieto, J. A., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg6241 · Cited by 20
“For this, we injected an AAV variant, ShH10, that selectively targets glia (27) with a coding sequence for Ocm preceded by a coding sequence for secretion (immunoglobulin κ) and a GFP tag Fig.”
MethodAdeno-associated virus vectors for retinal gene therapy in basic research and clinical studies
Xia, X., & Guo, X. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1310050 · Cited by 25
Andries, L., Groef, L. D., & Moons, L. (2019) · Current Eye Research · doi:10.1080/02713683.2019.1669664 · Cited by 20
Karan, B. M., Little, K., Augustine, J., Stitt, A. W., & Curtis, T. M. (2023) · Antioxidants · doi:10.3390/antiox12071466 · Cited by 18
Application and Expansion of Virus-Induced Gene Silencing for Functional Studies in Vegetables
Wang, Z., Cao, S., Xu, X., He, Y., Shou, W., Munaiz, E. D., Yu, C., & Shen, J. (2023) · Horticulturae · doi:10.3390/horticulturae9080934 · Cited by 21
“However, previous reports have shown that GFP expression is temporally correlated with VIGS effects and may reduce the infection efficiency [41,66].”
BackgroundAAV Gene Augmentation Therapy for CRB1-Associated Retinitis Pigmentosa
Alves, C. H., & Wijnholds, J. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7522-8_10 · Cited by 20
Kay, C. N., Ryals, R. C., Aslanidi, G., Min, S.-H., Ruan, Q., Sun, J., Dyka, F. M., Kasuga, D. T., Ayala, A. E., Vliet, K. V., et al. (2013) · PLoS ONE · doi:10.1371/annotation/99ee1789-a658-4fb0-8593-40a40e9f344a · Cited by 18
CRISPR-Cas9-mediated deletion of carbonic anhydrase 2 in the ciliary body to treat glaucoma
Jiang, J., Kong, K., Fang, X., Wang, D., Zhang, Y., Wang, P., Yang, Z., Zhang, Y., Liu, X., Aung, T., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101524 · Cited by 23
Dawn of ocular gene therapy: implications for molecular diagnosis in retinal disease
Zaneveld, J. E., Wang, F., Wang, X., & Chen, R. (2013) · Science China Life Sciences · doi:10.1007/s11427-013-4443-y · Cited by 17
Reichenbach, A., & Bringmann, A. (2015) · Colloquium Series on Neuroglia in Biology and Medicine From Physiology to Disease · doi:10.4199/c00122ed1v01y201412ngl003 · Cited by 21
Joly, S., Dalkara, D., & Pernet, V. (2017) · Neural Plasticity · doi:10.1155/2017/6818970 · Cited by 18
“CNTF cDNA was delivered using an adeno-associated virus (AAV) variant called ShH10 engineered to target Müller glia [16, 34].”
MethodSelf-citationCrosson, S. M., Bennett, A., Fajardo, D., Peterson, J. J., Zhang, H., Li, W., Leahy, M. T., Jennings, C. K., Boyd, R. F., Boye, S. L., et al. (2021) · Journal of Virology · doi:10.1128/jvi.02440-20 · Cited by 16
NRF2/ARE mediated antioxidant response to glaucoma: role of glia and retinal ganglion cells
Naguib, S. A., Backstrom, J. R., Artis, E., Ghose, P., Stahl, A. N., Hardin, R., Haider, A. A., Ang, J., Calkins, D. J., & Rex, T. S. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01663-1 · Cited by 21
“While we aimed to primarily transduce astrocytes with the combination of a 1 kb Vim promoter and a modified AAV6 capsid (ShH10 with an additional Y455F mutation) [31], we have not excluded the possibility that some Müller glia were also transduced following intravitreal injection.”
MethodAAV-Mediated Expression of Human VEGF, TNF-α, and IL-6 Induces Retinal Pathology in Mice
Weigelt, C. M., Fuchs, H., Schönberger, T., Stierstorfer, B., Strobel, B., Lamla, T., Ciossek, T., Bakker, R. A., & Redemann, N. H. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.11.15 · Cited by 18
Gene Therapy for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa
Massengill, M. T., & Lewin, A. S. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000383 · Cited by 20
Liu, J., Bassal, M., Schlichting, S., Braren, I., Spiezio, A. D., Säftig, P., & Bartsch, U. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105628 · Cited by 17
Channelrhodopsins—Their potential in gene therapy for neurological disorders
Ji, Z.-G., Ishizuka, T., & Yawo, H. (2012) · Neuroscience Research · doi:10.1016/j.neures.2012.09.004 · Cited by 17
Xiang, H., Xu, H., Fan, F., Shin, S., Hogan, Q. H., & Yu, H. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24183 · Cited by 15
“This indicates that although the divergent capsid residues in AAVshH10 and AAVshH19 may act in concert to improve glia transduction in the visual system or brain glioma (Byrne et al., 2013; Klimczak et al., 2009; Koerber et al., 2009; Pellissier et al., 2014; Vacca et al., 2016), this shift in tropism does not occur w…”
BackgroundInfluentialCreating an Ocular Biofactory: Surgical Approaches in Gene Therapy for Acquired Retinal Diseases
Xu, D. N., Khan, M., & Ho, A. C. (2021) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000362 · Cited by 19
“A directed evolution approach was used to design an AAV6-derived vector with increased tropism for retinal Muller cells.(49) Recombinant AAV have also been rationally designed with self-complementary vector sequences(50,51) and selected mutagenesis of tyrosine surface residues into other amino acids,(52,53) improving…”
Methodvan der Veen, I., Heredero Berzal, A., Koster, C., ten Asbroek, A. L. M. A., Bergen, A. A., & Boon, C. J. F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021267 · Cited by 14
“One group used AAVshH10, which is derived from the AAV6 shuffled library and primarily targets Müller cells [92].”
MethodRetinal Gene Therapy for Usher Syndrome: Current Developments, Challenges, and Perspectives
Dinculescu, A., Link, B. A., & Saperstein, D. A. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000378 · Cited by 15
Weigelt, C. M., Zippel, N., Fuchs, H., Rimpelä, A., Schönberger, T., Stierstorfer, B., Bakker, R. A., & Redemann, N. H. (2022) · Translational Vision Science & Technology · doi:10.1167/tvst.11.5.18 · Cited by 17
Boon, N., Alves, C. H., Mulder, A. A., Andriessen, C. A., Buck, T. M., Quinn, P. M. J., Vos, R. M., Koster, A. J., Jost, C. R., & Wijnholds, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073563 · Cited by 14
“transduction of mainly MGCs in the INL after intravitreal injection in new-born control and Crb1 mutant rats with ShH10Y, which is consistent with previously published data obtained in the adult rat [31].”
ResultTranslational Retinal Research and Therapies
Hardcastle, A. J., Sieving, P. A., Sahel, J., Jacobson, S. G., Cideciyan, A. V., Flannery, J. G., Beltran, W. A., & Aguirre, G. D. (2018) · Translational Vision Science & Technology · doi:10.1167/tvst.7.5.8 · Cited by 17
Self-citationDevelop an efficient and specific AAV-based labeling system for Muller glia in mice
Gao, Y., Fang, K., Yan, Z., Zhang, H., Geng, G., Wu, W., Ding, X., Zhang, H., Zhong, N., Wang, Q., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-27013-0 · Cited by 13
Challenges in AAV-Based Retinal Gene Therapies and the Role of Magnetic Nanoparticle Platforms
Siontas, O., & Ahn, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237385 · Cited by 13
“Previously, in 2009, DE-designed mutants for neuronal tissues were screened for their utility in IVI-mediated retinal transduction, whereby AAV2/ShH10 appeared to selectively transduce Müller cells, but not cell layers below, in rat eyes (Table 1) [72].”
Critical Examination of Müller Glia-Derived in vivo Neurogenesis in the Mouse Retina
Xie, Y., & Chen, B. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.830382 · Cited by 12
“2) the transduction efficiency, as well as the cell-type-specificity of AAVmediated gene transfer, can be largely influenced by AAV serotypes (Klimczak et al., 2009).”
BackgroundDengue Virus Infection of Human Retinal Müller Glial Cells
Oliver, G. F., Ashander, L. M., Dawson, A. C., Ma, Y., Carr, J. M., Williams, K. A., & Smith, J. R. (2023) · Viruses · doi:10.3390/v15071410 · Cited by 11
“Müller cells are targets for lentiviral [24] and adeno-associated viral vectors [25], and they also interact with extracellular pathogens, such as in bacterial endophthalmitis, in which they mediate early innate immune responses through expression of Toll-like receptors and inflammatory mediators, and are capable of p…”
BackgroundBiber, J., Jabri, Y., Glänzer, S., Dort, A., Hoffelner, P., Schmidt, C. Q., Bludau, O., Pauly, D., & Grosche, A. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03045-3 · Cited by 12
“By integrating a glia-specific promoter and using an AAV capsid with a preference for Müller cells [31], we were able to target the synthesis and subsequent release of these complement regulators predominantly to Müller glia.”
BackgroundMethodBurns, M. E., & Stevens, B. (2018) · eNeuro · doi:10.1523/eneuro.0035-18.2018 · Cited by 11
“Although there are several good markers for labeling Müller cells in the retina, including a custom AAV called Shh10 (Klimczak et al., 2009) that drives serotype-specific Müller cell transduction, there is a need for consistent analogous tools for labeling or manipulating astrocytes exclusively in the liv- March/April…”
BackgroundInfluentialLi, S., Hu, Y., Li, Y., Hu, M., Wang, W., Ma, Y., Cai, Y., Wei, M., Yao, Y., Wang, Y., et al. (2020) · 中国科学通报:英文版 · doi:10.1016/j.scib.2020.09.008 · Cited by 11
Xu, X., Xu, Z., Liu, J., Zhang, Z., Chen, H., Li, X., & Shi, S. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s109986 · Cited by 11
“As an intraocular administration, intravitreal injections are a more clinically applicable and practical route than subretinal injections.(10,20) Therefore, the relationship between small NP compositions and the diffusion and distribution after intravitreal injection of small NPs is very important.”
BackgroundIntrinsic and Induced Neuronal Regeneration in the Mammalian Retina
Woodworth, M. B., Greig, L. C., & Goldberg, J. L. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0309 · Cited by 12
“This issue could potentially be mitigated by also using an engineered viral capsid that preferentially infects particular cell types, such as the ShH10 variant of AAV6 that primarily infects Mu¨ller glia (Klimczak et al., 2009).”
Baek, H., Sariev, A., Kim, M., Lee, H., Kim, J., & Kim, H. (2018) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2018.8513138 · Cited by 10
“The following primary antibodies were used in immunochemistry for identifying cerebellar PCs in cerebellum and myeloperoxidase (MPO) positive neutrophils in ischemic cortical region: rabbit polyclonal anti-calbindin (1:1000 dilution, product code: ab11426) [18], mouse monoclonal antiMPO (1:50 dilution, product code: a…”
MethodPeripapillary Intravitreal Injection Improves AAV-Mediated Retinal Transduction
Madrakhimov, S. B., Yang, J. Y., Ahn, D. H., Han, J. W., Ha, T. H., & Park, T. K. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.018 · Cited by 11
La conception de vecteurs adaptés à la thérapie génique oculaire
Khabou, H., & Dalkara, D. (2015) · médecine/sciences · doi:10.1051/medsci/20153105015 · Cited by 17
“La rétine est également composée de trois types de cellules gliales permettant le maintien de l’homéostasie rétinienne : la microglie, l’astrocyte et la cellule gliale de Müller, cette dernière étant le type majoritaire.”
InfluentialSelf-citationCell-Based Therapies: Strategies for Regeneration
Pavlou, M., & Reh, T. A. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041306 · Cited by 11
Innovative gene delivery systems for retinal disease therapy
Wu, H., Dong, L., Jin, S., Zhao, Y.-W., & Zhu, L. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00797 · Cited by 12
“Additionally, the AAV variant ShH10 efficiently and selectively transduced murine MG via intravitreal injection (Klimczak et al., 2009), making it a valuable tool for in vivo MG reprogramming.”
Gene therapy for ocular hypertension using hfCas13d-mediated mRNA targeting
Chen, S., Liu, Z., Lo, C., Wang, Q. K., Ning, K., Zhāng, Q., Zhao, J., Shen, Y., & Sun, Y. (2025) · PNAS Nexus · doi:10.1093/pnasnexus/pgaf168 · Cited by 10
“NN. ShH10 serotype, an AAV6 variant (I319V, N451D, D532N), has higher transduction efficiency than AAV2/6 and efficiently transduces the ciliary body (15, 16).”
Glial cells as a promising therapeutic target of glaucoma: beyond the IOP
Shinozaki, Y., Namekata, K., Guo, X., & Harada, T. (2024) · Frontiers in Ophthalmology · doi:10.3389/fopht.2023.1310226 · Cited by 9
Engineered AAV vectors for improved central nervous system gene delivery
Kotterman, M. A., & Schaffer, D. V. (2015) · Neurogenesis · doi:10.1080/23262133.2015.1122700 · Cited by 10
“In addition, the D532N mutation appears to increase affinity to HSPG, which are not a receptor for the parental AAV6.(26) In a subsequent study, this vector mediated broad expression of glial cell-derived neurotropic factor (GDNF), which slowed retinal degeneration in a rat model of retinitis pigmentosa.”
BackgroundInfluentialSelf-citationWeinmann, J., Söllner, J. F., Abele, S., Zimmermann, G., Zuckschwerdt, K., Mayer, C. A., Danner-Liskus, J., Peltzer, A., Schuler, M. J., Lamla, T., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.109 · Cited by 16
Using Adeno-associated Virus as a Tool to Study Retinal Barriers in Disease
Vacca, O., Mathari, B. E., Darche, M., Sahel, J., Rendón, Á., & Dalkara, D. (2015) · Journal of Visualized Experiments · doi:10.3791/52451 · Cited by 9
Self-citationAdeno-associated virus vectors for human gene therapy
Chen, H. (2015) · World Journal of Medical Genetics · doi:10.5496/wjmg.v5.i3.28 · Cited by 9
Rodriguez, L., Joly, S., Mdzomba, J. B., & Pernet, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114100 · Cited by 6
“Sustained adeno-associated virus (AAV)-mediated release of CNTF in the retina has been shown to produce long-distance axonal regrowth in the mouse optic nerve [22,23].”
BackgroundZarbin, M. A., Leary, J. F., Montemagno, C. D., Ritch, R. H., & Humayun, M. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00036-9 · Cited by 7
Viral Vector Technologies and Strategies: Improving on Nature
Croze, R. H., Kotterman, M. A., Burns, C. H., Schmitt, C. E., Quezada, M., Schaffer, D. V., Kirn, D. H., & Francis, P. J. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000361 · Cited by 5
Self-citationGene Therapy for Central Nervous System in Duchenne Muscular Dystrophy
Vaillend, C., Zarrouki, F., & Vacca, O. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_24 · Cited by 5
A rAAV2/6 Mutant with Enhanced Targeting for Mouse Retinal Müller Cells
Cao, J., Liu, X., Yuan, Y., Wang, F., Kong, W., Shi, G., Li, W., & Zhang, C. (2019) · Current Eye Research · doi:10.1080/02713683.2019.1639768 · Cited by 5
“It has a mutation of four residues, I319V, N451D, D532N, and H642N.(26) Our study showed that rAAV2/6-S663L has a similar tropism toAAV6shH10 in the mouse retina.”
BackgroundAdeno-associated virus neutralising antibodies in type 1 diabetes mellitus
Andrzejewski, S., Murali, A., Ramlogan‐Steel, C. A., Edwards, K. P., Efron, N., Steel, J. C., & Layton, C. J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0076-5 · Cited by 6
Joly, S., Dodd, D. A., Grewe, B. F., & Pernet, V. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.06.010 · Cited by 4
“However, using new viral vectors such as engineered adenoassociated viruses called ShH10 [22, 35], it will be possible to determine the effect of Nogo-A overexpression on potassium flow across the Müller cell membrane after the isolation of cells infected in vivo.”
Becker, K., Weigelt, C. M., Fuchs, H., Viollet, C., Rust, W., Wyatt, H., Huber, J., Lamla, T., Fernández-Albert, F., Simon, E., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-23065-4 · Cited by 4
Nestin Regulates Müller Glia Proliferation After Retinal Injury
Motoyoshi, A., Saitoh, F., Iida, T., & Fujieda, H. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.14.8 · Cited by 5
“57 Alternatively, we favor the possibility that loss of nestin in Müller glia compromised their roles in retinal immune responses leading to aberrant microglia/macrophage activation.”
BackgroundOptogenetics: A Novel Therapeutic Avenue for Age-Related Macular Degeneration
Grenga, P., Ciancimino, C., Meduri, A., & Fragiotta, S. (2025) · Biomolecules · doi:10.3390/biom15091286 · Cited by 3
Gene Therapy for Retinal Diseases
Gopinath, C., Sarkar, S., & Ghosh, A. (2021) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-15-9184-6_30 · Cited by 3
2.202 – Engineering Viruses For Gene Therapy
Bergen, J., & Schaffer, D. (2011) · Elsevier eBooks · doi:10.1016/b978-0-08-055294-1.00061-1 · Cited by 2
Self-citationAAV-Mediated Gene Therapy for CRB1-Hereditary Retinopathies
Alves, C. H., & Wijnholds, J. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79308 · Cited by 5
“Pre-clinical studies in mice and rats showed that Müller glial cells can efficiently be infected after intravitreal administration of AAV2/6 or AAV2/shH10Y445F [15, 76], therefore these AAV capsids might be used to deliver CRB1 or CRB2 into Müller cells.”
BackgroundDuarte, F. T., & Arsenijévic, Y. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101424 · Cited by 2
Enhanced cellular secretion of AAV2 by expression of foreign viral envelope proteins
Kotterman, M. A., Koerber, J. T., Nam, J.-S., Cho, Y.-H., Kim, S., Jang, J.-H., & Lim, K. (2014) · Biochemical Engineering Journal · doi:10.1016/j.bej.2014.09.015 · Cited by 2
Self-citationShH10 viral vector for safe, efficient, and selective transduction of inner ear supporting cells
Bertken, Y. J., Kim, Y., Llamas, J., Beck, A., Nagiel, A., & Gnedeva, K. (2025) · Developmental Biology · doi:10.1016/j.ydbio.2025.07.013 · Cited by 1
4.33 Engineering Viruses For Gene Therapy
Bergen, J., & Schaffer, D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-100691-7.00167-1 · Cited by 1
Self-citationMichalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_150-1 · Cited by 1
Adeno-associated Viral Vectors in the Retina: Delivering Gene Therapy to the Right Destination
Rudnick, N. D., Kim, L. A., & Comander, J. (2022) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000416 · Cited by 1
Recent advances on modeling retinal disease: Towards efficient gene/drug therapy
Dolatabadi, E. N., Zaky, M. R. A., Abbas, F. H., Milani, A. E., André, H., & Alizadeh, E. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110416 · Cited by 1
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_150 · Cited by 1
Strategies for improving adeno-associated viral infection of airway epithelial cells
Dickey, D. D. (2012) · doi:10.17077/etd.m1aiqczb
“Directed evolution of AAV has been done in mice and rats in vivo, but this is the first time it has been performed in vivo in a large animal model such as the pig (104, 192, 193).”
Steines, B. R., Zabner, J., Meier, J. L., Adams, C. M., McCray, P. B., & Yeaman, C. A. (2015) · doi:10.17077/etd.tdj11wfe
Humphries, P., Humphries, M. M., Tam, L. C. S., Farrar, G. J., Kenna, P. F., Campbell, M., & Kiang, A. (2012) · SpringerBriefs in genetics · doi:10.1007/978-1-4614-4499-2_2
Anti-Angiogenic Gene Therapy: Basic Science and Challenges for Translation into the Clinic
Lange, C., & Bainbridge, J. W. (2016) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-3-319-24097-8_11
Graca, A. B. (2017) · UCL Discovery (University College London)
Engineering of Novel Adeno-Associated Virus Vectors for Gene Therapy Applications
Ortiz, S., & Luis, J. (2016) · Cited by 1
AAV-Nrf2 Mediated Rescue of Oxidative Stress in Mouse Models
Liang, K. J. (2015) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/tmc2-r921
Wei, Z., Liu, X., Li, T., Li, X., Zhou, Q., Wu, J., & Zhang, C. (2021) · Future Virology · doi:10.2217/fvl-2020-0096
Improved Strategies for Directed Evolution of Adeno-Associated Virus Gene Therapy Vectors
Ojala, D. S. (2017) · eScholarship (California Digital Library)
Critical Examination of Ptbp1-Mediated Glia-to-Neuron Conversion in the Mouse RetinaPreprint
Chen, B., Xie, Y., Zhou, J., & Guo, X. V. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3956655
Optimization of AAV tools to target Müller glial cells for retinal gene therapy
Urrutia-Cabrera, D., Huppert, G., Chu, S., Wang, L., Nguy, C. B., Liu, C.-F., Lisowski, L., Luu, C. D., Wang, J.-H., Hung, S. S. C., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201804
“11 Interestingly, Pellissier et al. reported some species difference in MG cell targeting specificity for ShH10 and ShH10Y viruses in mice compared to rats.”
InfluentialModulation of the intraocular immune environment by viral gene transfer in mouse models of uveitis
Chu, C. J. (2015) · UCL Discovery (University College London)
Biber, J., Jabri, Y., Glänzer, S., Dort, A., Hoffelner, P., Schmidt, C. Q., Bludau, O., Pauly, D., & Grosche, A. (2024) · Figshare · doi:10.6084/m9.figshare.26684625
Naguib, S. A., Backstrom, J. R., Artis, E., Ghose, P., Stahl, A. N., Hardin, R., Haider, A., Ang, J., Calkins, D. J., & Rex, T. S. (2024) · Figshare · doi:10.6084/m9.figshare.26631031
Naguib, S. A., Backstrom, J. R., Artis, E., Ghose, P., Stahl, A. N., Hardin, R., Haider, A., Ang, J., Calkins, D. J., & Rex, T. S. (2024) · Figshare · doi:10.6084/m9.figshare.26631034
Evolution dirigée de virus adéno-associés pour un transfert de gène efficace dans le système visuel
Planul, A. (2017) · theses.fr (ABES) · doi:10.70675/c9b178a1z8ba4z4451za409z4e80a603376f · Cited by 1
Müller Cells and Retinal Regeneration : The Role of the Hippo/YAP Signaling Pathway
García-García, D. (2020) · theses.fr (ABES) · doi:10.70675/8f64fd35z11c5z460fz8f49zb8e5b4e5e304
Elia, M., Pauzuolyte, V., Γεωργίου, Μ., Basche, M., Hansohn, C., Vasconcelos, E. J. R., Atkinson, R., Grellscheid, S., Johnson, C. A., Hilgen, G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.14.718379
Selecting Novel Retino-tropic AAV Capsids by Directed Evolution
Westhaus, A., & Lisowski, L. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5198-8_1
Transient YAP activation uncovers the neurogenic potential of proliferative mammalian Müller glia
Laserna, E., Saltykova, I. V., Hall, B. M., Tong, X., Dhindsa, J. S., Sarker, B., Hurley, A. E., Swinton, P. G., Lagor, W. R., Tran, N. M., et al. (2026) · PNAS Nexus · doi:10.1093/pnasnexus/pgag188 · Cited by 1
“For viral transduction, we selected the ShH10 capsid, a directed-evolution AAV6 variant reported to efficiently target MGs following intravitreal injection (12, 13).”
Metadata
- Authors
- Klimczak, R. R., Koerber, J. T., Dalkara, D., Flannery, J. G., & Schaffer, D. V.
- Affiliations
- University of California, Berkeley (US)
- Corresponding author
- Flannery, John G.
- Schaffer, David V.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-10-14
- Volume
- 4
- Issue
- 10
- Pages
- e7467
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2758586
- OpenAlex
- W2170160409
- Cited by
- 210
- References
- 49
- Citations by year
- 2026: 12 · 2025: 5 · 2024: 13 · 2023: 15 · 2022: 13 · 2021: 19 · 2020: 12 · 2019: 19 · 2018: 13 · 2017: 12 · 2016: 11 · 2015: 19 · 2014: 12 · 2013: 10 · 2012: 9
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Figshare (submittedVersion, cc-by)
- Funders
- National Heart, Lung, and Blood Institute (R01HL081527)
- National Eye Institute (PN2EY018241)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, Müller cells, intravitreal injection, retinal degeneration, gene delivery, retinal glia, neuroprotection, AAV tropism, directed evolution
- MeSH terms
- Dependovirus, Animals, Astrocytes, Cell Line, DNA Mutational Analysis, Genetic Vectors, Humans, Neuroglia, Retina, Retinal Diseases, Genetic Therapy, Rats, Sprague-Dawley, Gene Transfer Techniques, Rats, Retinal Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.